4-ethoxy-2,6-diethyl-benzaldehyde | 945408-21-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-ethoxy-2,6-diethyl-benzaldehyde
• 英文别名: 4-ethoxy-2,6-diethylbenzaldehyde
• CAS: 945408-21-9
• 化学式: C₁₃H₁₈O₂
• 分子量: 206.285
• InChiKey: BNAVZPGNIDAESA-UHFFFAOYSA-N

物化性质

• 沸点：
  317.0±37.0 °C(Predicted)
• 密度：
  0.995±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,6-diethyl-4-hydroxy-benzaldehyde 、 碘乙烷 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以88%的产率得到4-ethoxy-2,6-diethyl-benzaldehyde
  参考文献：
  名称：

  WO2007/85556

  摘要：

  公开号：

文献信息

• Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives
  申请人：Galley Guido

  公开号：US20070197621A1

  公开（公告）日：2007-08-23

  The present invention relates a method for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, R 1 , R 2 , A and n are as defined in the specification and to their pharmaceutically active salts. The invention also relates to novel compounds of formula I, pharmaceutical compositions containing them, and methods for their preparation.

  本发明涉及一种治疗抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病的方法，包括向个体施用化合物I的治疗有效量，其中R、R1、R2、A和n如规范中所定义，以及其药用活性盐。该发明还涉及化合物I的新颖化合物、含有它们的药物组合物以及它们的制备方法。
• Methods for treating CNS disorders with 4-imidazole derivatives
  申请人：Galley Guido

  公开号：US20070197622A1

  公开（公告）日：2007-08-23

  The present invention relates to methods for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, Ar, R 1 , R 1′ , R 2 , and n are as defined in the specification and to their pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers and tautomeric forms. The invention also relates to novel compounds of formula I, compositions containing them, and methods for their preparation.

  本发明涉及一种治疗抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关障碍、精神疾病，如精神分裂症、神经疾病，如帕金森病、神经退行性疾病，如阿尔茨海默病、癫痫、偏头痛、高血压、物质滥用和代谢性疾病，如进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和吸收的障碍、体温稳态的障碍和功能障碍、睡眠和昼夜节律的障碍以及心血管疾病的方法，包括向个体施用化合物I的治疗有效量，其中化合物I的R、Ar、R1、R1'、R2和n如规范中所定义，并且包括它们的药物活性盐、外消旋混合物、对映异构体和互变异构体。本发明还涉及化合物I的新型化合物、含有它们的组合物以及它们的制备方法。
• EP1981497A2
  申请人：——

  公开号：EP1981497A2

  公开（公告）日：2008-10-22
• EP1981880A2
  申请人：——

  公开号：EP1981880A2

  公开（公告）日：2008-10-22
• USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS
  申请人：F.HOFFMANN-LA ROCHE AG

  公开号：EP1981880B1

  公开（公告）日：2010-02-24